September 30, 2015
Intrinsic Therapeutics contracted with an independent partner, Fletcher Spaght Inc, to conduct a nation-wide survey aimed to understand the U.S. surgeon perspective for the need to improve discectomy outcomes and to identify potential barriers to adopting anular closure. A total of 38 U.S. orthopedic and neurosurgeons were interviewed through one of two methods: an in-depth phone interview, or a pre- and post-survey following attendance of the Barricaid® symposium, that took place on the 19 September in Boston, MA.
A large proportion of the surgeons (~80%) that took part in the survey rated the clinical need to reduce reherniations as significant to very significant. Responding surgeons anticipate that on average 34% of their patients are eligible for Barricaid®. In addition, 95% of the respondents are likely to use Barricaid® in an environment with reimbursement.